Phase I Clinical Trial and Pharmacokinetic Study

infusion solutions are compatible with PVC i.v. infusion bags and are chemically stable ... two cycles of treatment. Disease assessments by any tech- ...

2 downloads 0 Views 168KB Size

Recommend Documents

Center, San Antonio, Texas 78284 ¡T.E. W.]; and Burroughs Wellcome Company, Research Triangle ... patients who were also monitored following a single i.v. dose of 140 and ... plasma concentration-time curve to be accurately predicted from the 3- ...

Apr 9, 2017 - to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

In a phase 2 study of raltitrexed, cisplatin, and 5- fluorouracil administered to .... nitroacetanilide, was obtained from Sigma-Aldrich (Milwaukee,. WI). Twenty-five ...

Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with. Advanced Cancer1. Sridhar Mani,2 ...

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

p.o., but this route of administration has several limitations. The bioavailability of MP is low. (approximately. 16%), and the resulting plasma concen- trations exhibit ..... for the tram- fer ofTG toand from the peripheral compartment;. Xe,, the am

bocytopenia occurring in 3 of 15, 4 of 9, and 2 of 2 patients in the first, second, and third ... half-lives were 15.9 ±4.6 and 90 ±13 h, respectively. No objective.

in Serum of Cancer Patients: Phase I Clinical Trial. Jose A. Baptista,1 ... (1), sub- sequently from. North. American plants of the ganera. Astragulus .... Gal in H20.

Center, Salt Lake City, UT; Grant CA 26126, Robert Wells of the. Children's Hospital ..... Giguere, V., Ong, E. S., Segui, P., and Evans, R. M. Identification of a receptor for the .... Brazell, R. K., Vane, F. M., Ehmann, C. W., and Colburn, W. A..

Apr 12, 2017 - Sorafenib (Nexavar) is an orally bioavailable small-mol- ecule inhibitor (molecular weight, 465 g/mole) of multiple kinases controlling tumor ...

Robert J. Motzer,2 Subhash C. Gulati, William P.Tong, Celia Menendez-Botet, Peter ... •'the Department of Clinical Chemistry [C. M-B.j: and the Department of ...

starting dose of POH was 1600 mg/m2/dose, with escala- tions to 2100 ...... Elegbede, J. A., Elson, C. E., Qureshi, A., Tanner, M. A., and Gould,. M. N. Inhibition of ...

Jul 15, 2006 - suggested that G1 arrest induced by EGFR TKI interferes with the cell cycle .... Dassonville O, Formento JL, Francoual M, et al. Expression of ...

derived from breast (MDA-MB-435), colorectal (RKO, HT-29, ..... 2019. 625. 1857. 1077. 4208. 2903. 2434. Ctrough e (ng/ml). Ro 31-7453. 54.2. 145. 72. 361.

C. G. Haase5, D. Voliotis5 & D. Strumberg2* ... 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600mg/m2/day for 1 day every. 3 weeks ..... 38-3441. Plasma samples were analyzed for BAY 38-3441 and CPT using.

May 15, 2009 - Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour ... Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy ...

standard samples containing blank plasma spiked with prino- mastat and AG3473 were ... An API III Perkin-Elmer Sciex LC/MS using positive ion electrospray ...

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile of paclitaxel (20).

Oct 13, 2009 - pared with prior studies of the parental antibody hu3S193. These results ... humanized monoclonal antibody based on the anti-Ley anti-.

Dec 15, 2005 - Anthony W.Tolcher,1and Eric K. Rowinsky1. Abstract Purpose:To ...... Tricoli JV, Sahai BM, McCormick PJ, Jarlinski SJ,. Bertram JS, Kowalski D.

Abstract. Purpose: VNP40101M is a novel sulfonylhydrazine al- kylating agent with broad antitumor activity in animal mod- els. As alkylating agents are ...